• Acadia Pharmaceuticals Inc., of San Diego, said underwriters exercised in full their overallotment option to purchase 862,500 shares of common stock in connection with the public offering priced April 4 at $15.50 per share. The overallotment brings the total shares offered to 6.6 million and brought in proceeds to Acadia of about $96.1 million. Banc of America Securities Inc. and Lehman Brothers Inc. served as the book-running managers, with Deutsche Bank Securities serving as co-lead manager and Piper Jaffray & Co., JMP Securities LLC and Rodman & Renshaw LLC acting as co-managers. (See BioWorld Today, April 6, 2007.)

• Argos Therapeutics Inc., of Durham, N.C., raised $5 million in a three-year financing arrangement with Silicon Valley Bank and Oxford Finance Corp. The money will be used primarily to fund three ongoing clinical trials of the company's personalized RNA-loaded dendritic cell-based immunotherapy technology: a Phase II study in renal-cell carcinoma, a Phase I/II trial in chronic lymphocytic leukemia and a Phase I trial in HIV. Argos anticipates reporting response data from the CLL trial this year, as well as immune response and safety data from the HIV study.

• CytRx Corp., of Los Angeles, completed a previously announced private placement, raising $37 million. The company placed 8.6 million shares priced at $4.30 each. Net proceeds are about $34.4 million and will go toward an investment of at least $15 million for working capital and general corporate purposes in the company's majority-owned subsidiary, RXi Pharmaceuticals Corp., and the remainder being used to augment CytRx's working capital and general corporate purposes, including further development work and clinical trials of its lead candidates. Lehman Brothers acted as the lead placement agent, with Oppenheimer & Co. Inc., Griffin Securities Inc. and Pulse Obsidian, a division of Pulse Trading Inc., serving as co-placement agents. (See BioWorld Today, April 19, 2007.)

• Microbix Biosystems Inc., of Toronto, completed a private placement, offering 1.5 million units at 70 cents apiece for gross proceeds of $1.05 million. Each unit consists of one common share and one-half of a common share purchase warrant. Each whole warrant entitles the holder to subscribe for one common share priced at 90 cents for a period of 18 months. Microbix said the investor is a large Canadian financial institution. Funds will help the company proceed with its previously announced financing arrangement for its Urokinase product, which is in development for dissolving blood clots and in cancer therapies.

• NuGEN Technologies Inc., of San Carlos, Calif., received $3 million in committed debt financing from Hercules Technology Growth Capital Inc. NuGEN develops nucleic acid amplification and labeling systems and said the financing will be used to develop new products and increase marketing efforts for existing products.

No Comments